Biomimetic Nanotechnology: A Natural Path Forward for Tumor-Selective and Tumor-Specific NIR Activable Photonanomedicines.
Biomimetic Nanotechnology: A Natural Path Forward for Tumor-Selective and Tumor-Specific NIR Activable Photonanomedicines.
复制标题
DOI：
10.3390/pharmaceutics13060786
复制
发表时间：
2021-05-25
期刊：
影响因子：
5.4
通讯作者：
Obaid G
中科院分区：
文献类型：
--
作者：
Prajapati S;Hinchliffe T;Roy V;Shah N;Jones CN;Obaid G
仿生纳米技术的出现在过去十年中出现了指数增长，应用于再生医学，免疫治疗和药物输送。在近红外（NIR）光动力学过程（photonanomedicines; PNM）激活的纳米医学的背景下，仿生纳米技术正在推动可激活的肿瘤靶向纳米级药物递送系统的边界。这篇综述讨论了如何利用一个独特的集体生物过程的关键目标的实体瘤，仿生PNM（bPNM）可以赋予肿瘤细胞特异性和肿瘤选择性光动力治疗为基础的组合方案。通过分子免疫逃避和自我识别，bPNM可以分别赋予肿瘤选择性（优先的大块肿瘤积累）和肿瘤特异性（对癌细胞的离散分子亲和力）。他们这样做的方式是类似的，但可以说上级，合成分子靶向的PNM。一个特别强调的是如何bPNM可以被工程化，以规避肿瘤细胞的异质性，这被认为是分子靶向治疗的阿喀琉斯之踵。前瞻性的主张也提出了如何患者的肿瘤异质性，最终可以概括为制造患者特异性，异质性靶向bPNM。
The emergence of biomimetic nanotechnology has seen an exponential rise over the past decade with applications in regenerative medicine, immunotherapy and drug delivery. In the context of nanomedicines activated by near infrared (NIR) photodynamic processes (photonanomedicines; PNMs), biomimetic nanotechnology is pushing the boundaries of activatable tumor targeted nanoscale drug delivery systems. This review discusses how, by harnessing a unique collective of biological processes critical to targeting of solid tumors, biomimetic PNMs (bPNMs) can impart tumor cell specific and tumor selective photodynamic therapy-based combination regimens. Through molecular immune evasion and self-recognition, bPNMs can confer both tumor selectivity (preferential bulk tumor accumulation) and tumor specificity (discrete molecular affinity for cancer cells), respectively. They do so in a manner that is akin, yet arguably superior, to synthetic molecular-targeted PNMs. A particular emphasis is made on how bPNMs can be engineered to circumvent tumor cell heterogeneity, which is considered the Achilles’ heel of molecular targeted therapeutics. Forward-looking propositions are also presented on how patient tumor heterogeneity can ultimately be recapitulated to fabricate patient-specific, heterogeneity-targeting bPNMs.
登录
查看更多内容
DOI：
10.1073/pnas.1808790115
发表时间：
2018-11-13
影响因子：
11.1
作者：
Bausch-Fluck D;Goldmann U;Müller S;van Oostrum M;Müller M;Schubert OT;Wollscheid B
通讯作者：
Wollscheid B
影响因子：
13.3
作者：
Alhasan, Ali H.;Patel, Pinal C.;Choi, Chung Hang J.;Mirkin, Chad A.
通讯作者：
Mirkin, Chad A.
影响因子：
2.5
作者：
Feng, Jinjie;Wang, Shuyan;Wang, Luping
通讯作者：
Wang, Luping
影响因子：
10.8
作者：
Aslund, Andreas K. O.;Berg, Sigrid;Davies, Catharina de Lange
通讯作者：
Davies, Catharina de Lange
影响因子：
16.6
作者：
Carter, Kevin A.;Shao, Shuai;Hoopes, Matthew I.;Luo, Dandan;Ahsan, Bilal;Grigoryants, Vladimir M.;Song, Wentao;Huang, Haoyuan;Zhang, Guojian;Pandey, Ravindra K.;Geng, Jumin;Pfeifer, Blaine A.;Scholes, Charles P.;Ortega, Joaquin;Karttunen, Mikko;Lovell, Jonathan F.
通讯作者：
Lovell, Jonathan F.